Cempra Stock Analysis (NASDAQ:CEMP)

Add to My Stocks
$3.35 $0.17 (5.35%) CEMP stock closing price Feb 17, 2017 (Closing)
Watch Robo Advisor Video of CEMP Stock Analysis
Cempra
Updated on : Feb 17, 2017
previous close
CEMP 3.4 (0%)
S&P 500 2351.2 (0%)
Closing Price On: Feb 17, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-673.1%
Sector Average:
-1.1%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Debt/Equity Ratio
Debt:
17M
Debt/Equity Ratio:
 0.08
Compared to the industry
Cash Flow
Operating cash flow:
-$29.4M
Net Income:
-$32.3M
PROS      CONS
Low Debt Burden
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
CEMP PS :
11
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-62.9%
Free Cash Flow Margin:
-740.6%
Double Tap To Exit Full Screen
0:00
/

Cempra Analysis Video

135 5 2

View Cempra stock analysis video. This is our CEMP analyst opinion covering the buy and sell arguments for CEMP stock.

Cempra Inc Stock Rating (1.7/5)

Our Cempra stock opinion is based on fundamentals of the company. This Cempra stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy CEMP stock?

  • With its debt/equity ratio of  0.08, Cempra has a lower debt burden when compared to the Medical average.

Should you sell CEMP stock?

  • Cempra reported an average operating margin of -673.1% over the Last Twelve Months (LTM).
  • Cempra registered an average TTM Net loss of -679%.
  • The company does not have profits. Hence the PE ratio is meaningless for CEMP stock.
  • CEMP stock is trading at a PS multiple of 11, which is a negative when compared to the Medical-Drugs industry average multiple of 4.7.
  • Cempra has a negative return on equity of -62.9%. This indicates that the firm is inefficient at generating profits.
  • The company has a negative free cash flow margin of -740.6%.

Comments on this video and Cempra stock